Abstract Objective To evaluate the clinical efficacy of short-peptide exclusive enteral nutrition (EEN) therapy in inducing remission during active Crohn's disease (CD) in children, as well as changes in physical growth and nutritional indicators before and after treatment. Methods A prospective study included 43 children with active CD who were admitted to the Department of Gastroenterology, Children's Hospital of Nanjing Medical University from January 2017 to January 2024. The participants were randomly divided into a medication treatment group (13 children) and a short-peptide + medication treatment group (30 children). The changes in the Pediatric Crohn's Disease Activity Index (PCDAI) scores, physical growth, and nutritional indicators before and after treatment were analyzed in both groups. Results The PCDAI scores in the short-peptide + medication treatment group were lower than those in the medication treatment group after treatment (P<0.05). The Z-scores for weight-for-age, body mass index, and albumin levels were higher in the short-peptide + medication treatment group compared to the medication treatment group (P<0.05). In the patients with moderate to severe CD, total protein levels in the short-peptide + medication treatment group were significantly higher than those in the medication treatment group (P<0.05). Conclusions Short-peptide EEN therapy can induce clinical remission in children with active CD and promote their physical growth while improving their nutritional status.
Corresponding Authors:
Yang HEmail：xinghui7325@sina.com。
E-mail: xinghui7325@sina.com
Cite this article:
YANG Min,WU Run-Qiu,CHEN Wen-Xin et al. Impact of short-peptide exclusive enteral nutrition therapy on physical growth and nutritional status in children with Crohn's disease[J]. CJCP, 2024, 26(9): 933-939.
YANG Min,WU Run-Qiu,CHEN Wen-Xin et al. Impact of short-peptide exclusive enteral nutrition therapy on physical growth and nutritional status in children with Crohn's disease[J]. CJCP, 2024, 26(9): 933-939.
Wu R, Yang J, Cao J, et al. Efficacy of short-chain polypeptide-based EEN formulas in alleviating intestinal injury in children with Crohn's disease: a single-center study in China[J]. Front Nutr, 2023, 10: 931004. PMID: 37215203. PMCID: PMC10198436. DOI: 10.3389/fnut.2023.931004.
Zhang J, Yu WQ, Wei T, et al. Effects of short-peptide-based enteral nutrition on the intestinal microcirculation and mucosal barrier in mice with severe acute pancreatitis[J]. Mol Nutr Food Res, 2020, 64(5): e1901191. PMID: 31965752. DOI: 10.1002/mnfr.201901191.
Ibrahim H, Mansour M, El Gendy YG. Peptide-based formula versus standard-based polymeric formula for critically ill children: is it superior for patients' tolerance?[J]. Arch Med Sci, 2020, 16(3): 592-596. PMID: 32399107. PMCID: PMC7212209. DOI: 10.5114/aoms.2020.94157.
Shahid N, Salman F, Makhdum M. Major factors responsible for child malnutrition: a review[J]. J Pak Med Assoc, 2021, 71(2(B)): 729-733. PMID: 33941968. DOI: 10.47391/JPMA.1243.
Fernández Montes R, Urbano Villaescusa J, Carrillo álvarez á, et al. Effect of three enteral diets with different protein contents on protein metabolism in critically ill infants: a randomized controlled trial[J]. An Pediatr (Engl Ed), 2023, 99(1): 26-36. PMID: 37344303. DOI: 10.1016/j.anpede.2023.03.011.
Capriati T, Bizzarri C, Dilillo A, et al. Growth failure in Crohn's disease children: may the first treatment have a role?[J]. Expert Rev Clin Immunol, 2019, 15(1): 97-104. PMID: 30403894. DOI: 10.1080/1744666X.2019.1543590.
Duchatellier CF, Kumar R, Krupoves A, et al. Steroid administration and growth impairment in children with Crohn's disease[J]. Inflamm Bowel Dis, 2016, 22(2): 355-363. PMID: 26752463. DOI: 10.1097/MIB.0000000000000669.
Atia O, Goren I, Fischler TS, et al. 5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease: a nationwide cohort study[J]. Aliment Pharmacol Ther, 2023, 57(9): 1004-1013. PMID: 36894866. DOI: 10.1111/apt.17419.
Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial[J]. Gut, 2022, 71(1): 34-42. PMID: 33384335. PMCID: PMC8666701. DOI: 10.1136/gutjnl-2020-322339.
Alhagamhmad MH, Day AS, Lemberg DA, et al. Exploring and enhancing the anti-inflammatory properties of polymeric formula[J]. JPEN J Parenter Enteral Nutr, 2017, 41(3): 436-445. PMID: 26826259. DOI: 10.1177/0148607115625627.
Lecleire S, Hassan A, Marion-Letellier R, et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways[J]. J Nutr, 2008, 138(12): 2481-2486. PMID: 19022976. DOI: 10.3945/jn.108.099127.
Ranasinghe RN, Biswas M, Vincent RP. Prealbumin: the clinical utility and analytical methodologies[J]. Ann Clin Biochem, 2022, 59(1): 7-14. PMID: 32429677. DOI: 10.1177/0004563220931885.
van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2020: jjaa161. PMID: 33026087. DOI: 10.1093/ecco-jcc/jjaa161.
